Stock Events

Stock Events

Relay Therapeutics 

$19.04
62
+$0.03+0.16% Friday 20:00
+$0.00+0%Friday 23:30After hours

Statistics

Day High
19.08
Day Low
19.02
52W High
21.27
52W Low
3.86
Volume
75,458
Avg. Volume
-
Mkt Cap
4.17B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.56
-0.5
-0.43
-0.36
Expected EPS
-0.398181
Actual EPS
N/A

Financials

-1,800.58%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
15.36MRevenue
-276.48MNet Income

Analyst Ratings

25.91Average Price Target
The highest estimate is 31.00.
From 11 ratings within the last 6 months. This is not an investment recommendation.
Buy
82%
Hold
18%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RLAY. It's not an investment recommendation.
NVIDIA
12
NVDA
Amazon
11
AMZN
Microsoft
10
MSFT
Apple
9
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is a direct competitor in the development of treatments for cystic fibrosis and other serious diseases, areas where Relay Therapeutics also aims to innovate.
Novartis
NVS
Mkt Cap292.35B
Novartis is a large pharmaceutical company with a broad portfolio that includes innovative therapies in areas where Relay Therapeutics is also active.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb has a strong presence in the oncology market, directly competing with Relay Therapeutics' cancer-focused pipeline.
AMGEN
AMGN
Mkt Cap233.78B
Amgen's focus on biologics in various therapeutic areas, including oncology and inflammatory diseases, places it in competition with Relay Therapeutics.
Merck
MRK
Mkt Cap366B
Merck is known for its strong oncology portfolio, especially in immunotherapy, which competes with Relay Therapeutics' cancer treatment research.
Pfizer
PFE
Mkt Cap159.36B
Pfizer's extensive research in oncology and other therapeutic areas makes it a competitor to Relay Therapeutics.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, with its focus on antiviral drugs and cancer therapies, competes in the same space as Relay Therapeutics.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie's work in oncology and immunology, including both small molecules and biologics, positions it as a competitor to Relay Therapeutics.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca has a diversified portfolio in oncology, cardiovascular, renal, metabolism, and respiratory diseases, competing with Relay Therapeutics in multiple areas.

About

Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
Show more...
CEO
Sanjiv K. Patel
Employees
192
Country
United States
ISIN
US75943R1023

Listings

BOATS
BOATS
RLAY.BOATS
XNAS
US
RLAY

0 Comments

Share your thoughts

FAQ

What is Relay Therapeutics stock price today?▼
The current price of RLAY is $19.04 USD — it has increased by +0.16% in the past 24 hours. Watch Relay Therapeutics stock price performance more closely on the chart.
What is Relay Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Relay Therapeutics stocks are traded under the ticker RLAY.
Is Relay Therapeutics stock price growing?▼
RLAY stock has risen by +1.44% compared to the previous week, the month change is a -3.3% fall, over the last year Relay Therapeutics has showed a +362.14% increase.
What is Relay Therapeutics market cap?▼
Today Relay Therapeutics has the market capitalization of 4.17B
When is the next Relay Therapeutics earnings date?▼
Relay Therapeutics is going to release the next earnings report on November 11, 2026.
What were Relay Therapeutics earnings last quarter?▼
RLAY earnings for the last quarter are -0.41 USD per share, whereas the estimation was -0.39 USD resulting in a -4.84% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Relay Therapeutics revenue for the last year?▼
Relay Therapeutics revenue for the last year amounts to 15.36M USD.
What is Relay Therapeutics net income for the last year?▼
RLAY net income for the last year is -276.48M USD.
How many employees does Relay Therapeutics have?▼
As of September 05, 2026, the company has 192 employees.
In which sector is Relay Therapeutics located?▼
Relay Therapeutics operates in the Health & Wellness sector.
When did Relay Therapeutics complete a stock split?▼
Relay Therapeutics has not had any recent stock splits.
Where is Relay Therapeutics headquartered?▼
Relay Therapeutics is headquartered in CAMBRIDGE, United States.